Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa
Movement Disorders Clinical Practice · 2024-07 · 11 (7) · 861-866
DOI: 10.1002/mdc3.14018 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 11.03.2024. Verfasst von K Ray Chaudhuri und 11 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson's Foundation International Centre of Excellence, King's College Hospital, London, UK. Hauptthemen laut MEDLINE: Quality of Life, Carbidopa, Levodopa, Drug Combinations. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie Inc.
Abstract (Originalsprache)
Background
Foslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs.
Objectives
Assess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167).
Methods
Pearson correlations between sleep (Parkinson's Disease Sleep Scale‐2 [PDSS‐2]) and quality of life (QoL; Parkinson's Disease Questionnaire‐39), motor experiences of daily living (m‐EDL; Movement Disorder Society‐Unified Parkinson's Disease Scale Part II), and “Off”/“On” times were calculated for baseline and week 26 improvements. Regression analyses were adjusted for baseline PDSS‐2 score.
Results
Baseline sleep correlated moderately with QoL ( r = 0.44, P < 0.001) and weakly with m‐EDL ( r = 0.28; P < 0.001). Sleep improvement weakly correlated with improved “Off” time ( r = 0.37; P < 0.001) and QoL ( r = 0.36; P < 0.001). Regression analyses demonstrated significant positive associations for improved sleep, “Off” time, QoL, and m‐EDL.
Conclusions
Improved sleep with foslevodopa/foscarbidopa was associated with improved QoL and “Off” time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Parkinson's Foundation International Centre of Excellence, King's College Hospital, London, UK.
- King's College Institute of Psychiatry, Psychology & Neuroscience, London, UK.
- AbbVie Inc., North Chicago, Illinois, USA.
- Department of Neurology, AZ St-Jan Brugge-Oostende AV, Bruges, Belgium.
- Department of Neurology, Ghent University Hospital, Ghent, Belgium.
- Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden.
ORCID-Profile: K Ray Chaudhuri, Bruno Bergmans, Filip Bergquist, Susan R Criswell, Yohei Mukai, Rajesh Pahwa
Förderung
- AbbVie Inc
Zitieren
APA
Chaudhuri, K. R., Facheris, M. F., Bergmans, B., Bergquist, F., Criswell, S. R., Jia, J., Kukreja, P., Mukai, Y., Spiegel, A. M., Gupta, R., Bergmann, L., & Pahwa, R. (2024). Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa. Movement Disorders Clinical Practice, 11(7), 861-866. https://doi.org/10.1002/mdc3.14018
Vancouver
Chaudhuri KR, Facheris MF, Bergmans B, Bergquist F, Criswell SR, Jia J, et al. Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa. Movement Disorders Clinical Practice. 2024;11(7):861-866. doi:10.1002/mdc3.14018
BibTeX
@article{Chaudhuri2024,
author = {Chaudhuri, K Ray and Facheris, Maurizio F and Bergmans, Bruno and Bergquist, Filip and Criswell, Susan R and Jia, Jia and Kukreja, Pavnit and Mukai, Yohei and Spiegel, Amy M and Gupta, Resmi and Bergmann, Lars and Pahwa, Rajesh},
title = {Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa},
journal = {Movement Disorders Clinical Practice},
year = {2024},
volume = {11},
number = {7},
pages = {861--866},
doi = {10.1002/mdc3.14018}
}
EUVIMED